

RESEARCH

Open Access

Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Ekua W Brenu^{1,2}, Mieke L van Driel^{1,2}, Don R Staines^{1,3}, Kevin J Ashton², Sandra B Ramos², James Keane², Nancy G Klimas⁴ and Sonya M Marshall-Gradisnik^{1,2*}

Abstract

Background: Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is characterised by severe prolonged fatigue, and decreases in cognition and other physiological functions, resulting in severe loss of quality of life, difficult clinical management and high costs to the health care system. To date there is no proven pathomechanism to satisfactorily explain this disorder. Studies have identified abnormalities in immune function but these data are inconsistent. We investigated the profile of markers of immune function (including novel markers) in CFS/ME patients.

Methods: We included 95 CFS/ME patients and 50 healthy controls. All participants were assessed on natural killer (NK) and CD8⁺T cell cytotoxic activities, Th1 and Th2 cytokine profile of CD4⁺T cells, expression of vasoactive intestinal peptide receptor 2 (VPACR2), levels of NK phenotypes (CD56^{bright} and CD56^{dim}) and regulatory T cells expressing FoxP3 transcription factor.

Results: Compared to healthy individuals, CFS/ME patients displayed significant increases in IL-10, IFN- γ , TNF- α , CD4⁺CD25⁺ T cells, FoxP3 and VPACR2 expression. Cytotoxic activity of NK and CD8⁺T cells and NK phenotypes, in particular the CD56^{bright} NK cells were significantly decreased in CFS/ME patients. Additionally granzyme A and granzyme K expression were reduced while expression levels of perforin were significantly increased in the CFS/ME population relative to the control population. These data suggest significant dysregulation of the immune system in CFS/ME patients.

Conclusions: Our study found immunological abnormalities which may serve as biomarkers in CFS/ME patients with potential for an application as a diagnostic tool.

Background

Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) remains a medically unexplained disorder despite numerous scientific investigations undertaken worldwide. The current worldwide prevalence rate of CFS/ME is estimated to be about 0.5% [1] with a higher prevalence in females compared to males, at a ratio of up to 6:1 [2]. The annual cost for treatment and management of CFS/ME in the USA is estimated to be US\$319 million with a direct cost of US\$7,406 per patient [3].

Generally, patients with CFS/ME experience severe fatigue, neuropsychological impairments, and other associated flu-like symptoms before a firm diagnosis of CFS/ME is made [4]. CFS/ME has been observed to persist for more than six months where symptoms may decrease, remain stable or worsen [3]. The current diagnostic strategy for health professionals is based on case definition, although this is not the most ideal method as it permits misdiagnosis. CFS/ME may share homology with certain disorders classified as fatigue related disorders where individuals experience fatigue and one or more of CFS/ME related symptoms. Further, there are no biomarkers available to affirm diagnosis thus complicating treatment.

* Correspondence: smarshal@bond.edu.au

¹Population Health and Neuroimmunology Unit, Faculty of Health Science and Medicine, Bond University, Robina, Queensland, Australia
Full list of author information is available at the end of the article

Population based studies have suggested a link between infections, neurological and neuroimmune dysfunctions and clinical manifestations of CFS/ME [5-10]. Immunity has been widely investigated in patients with CFS/ME but the results of these studies are inconsistent, reporting different lymphocyte cell numbers and cytokine distributions in patients with CFS/ME. Nonetheless, findings on immunoglobulins, complement markers and activation molecules in CFS/ME, may demonstrate an underlying infringement in immune function [8,11,12]. Decreased function of lymphocytes, in particular Natural Killer (NK) cell cytotoxic activity in CFS/ME patients compared to healthy controls, seems to be a consistent finding [13-16]. The functional capacity of other immune cells, such as T cells, and the contribution of other molecules in the pathophysiological mechanism of CFS/ME, remains to be determined. In particular, the role of subsets of CD4⁺T and the CD8⁺T cell populations has not been fully studied in CFS/ME. Importantly, recent data on cytokine distribution in CFS/ME patients point towards an increase in pro-inflammatory cytokines suggesting the presence of an underlying viral prevalence in these patients [17,18] and this can be detrimental to the immune inflammatory processes.

It is widely known that neuropeptides regulate immunity. Relevant among these are vasoactive neuropeptides (VNs), specifically vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP). They regulate and suppress pro-inflammatory immune processes via the PKA/cAMP pathway [19]. Their role in CFS/ME remains unknown although there are suggestions that they may be implicated in CD4⁺T cell related activities such as cytokine secretion and FoxP3 expression [20].

Immune cell numbers may not necessarily be indicative of diseased states, as stated previously these have been shown to be inconsistent in CFS/ME. However, the functional capacity of these cells during disease progression may provide a better understanding of the mechanism associated with unexplained disorders such as CFS/ME. Alternatively, this may help in identifying specific immune parameters that can be used as diagnostic markers for CFS/ME. The present study thus explores immunological abnormalities that may serve as biomarkers for diagnosing CFS/ME. Additionally, this is the first study to examine the role of VNs, VIP and PACAP, and FoxP3 expression in CFS/ME.

Methods

The project having been reviewed under an Expedited Review Procedure was granted approval to proceed by the Bond University Human Research Ethics Committee (BUHREC). All participants in this present study signed

an informed consent approved by the Bond University Human Research Ethics Committee (BUHREC).

Participants

All participants, both CFS/ME and non-fatigued controls were recruited from Queensland and New South Wales states in Australia through the CFS/ME support groups, newspaper and email advertisements into a prospective study as cases (CFS/ME patients) or non-fatigued controls (healthy volunteers). Participants were eligible if they were between 25 and 65 years old. Prior to inclusion all participants completed a consent form and a Chronic Fatigue Syndrome questionnaire based on the Centre for Disease Prevention and Control case definition (CDC 1994) [4]. Participants previously diagnosed with autoimmune disorders, psychosis, epilepsy, heart disease, or who were pregnant or breastfeeding were excluded from the study (Figure 1).

Sample Preparation and Routine Measurements


A volume of 25 ml of blood was collected from the antecubital vein of participants into lithium heparinised and EDTA collection tubes between 9 am and 11 am. Blood samples were analysed within 12 hours of collection. Routine blood cell counts for red blood cells, lymphocytes, granulocytes and monocytes were performed using an automated cell counter (ACT Differential Analyzer, Beckman Coulter, Miami, FL).

Assessment of NK Cytotoxic Activity

NK cells were isolated from whole blood samples using Ficoll-Hypaque (GE Healthcare Life Sciences; Milan, Italy) density gradient centrifugation. NK lymphocyte cytotoxic activity was performed as previously described [21]. Briefly, isolated cells were labelled with 0.4% PKH-26 (Sigma, St Louis, MO). NK cells were incubated with K562 cells at an effector to target ratio of 25: 1, for 4 hours at 37°C in 95% air, 5% CO₂. Apoptosis of the tumour cells was measured via FACS-Calibur flow cytometry using the Cell Quest Software (Becton Dickinson (BD), San Diego, CA), using Annexin V-FITC and 7-AAD reagent (BD Pharmingen, San Diego, CA). Percent lysis of K562 cells was calculated as previously described [21].

Assessment of CD8⁺T lymphocyte Cytotoxic Activity

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples using Ficoll-Hypaque (GE Healthcare Life Sciences; Milan, Italy) density gradient centrifugation. CD8⁺T lymphocytes were preferentially isolated from PMBCs using CD8⁺T cell isolation kit (Miltenyi Biotec GmbH; Bergisch-Gladbach, Germany) according to the manufacturer's instructions. Briefly, cells were stained with a CD8⁺T cell biotin-antibody cocktail, incubated for 10 minutes and then



stained with CD8⁺T cell micorbead cocktail for 15 minutes. Cells were then passed through separation columns where cells of interest were collected for further analysis. Cytolysis was performed as previously described using P815 cells as the target cells [22]. In brief, P815 cells were stained with 0.4% PKH-26 and activated using anti-CD3 (BD Bioscience, San Diego, CA). The target cells were then incubated with CD8⁺T cells at an effector to target ratio of 25: 1, for 4 hours at 37°C in 95% air, 5% CO₂. Annexin V-FITC flow cytometry apoptosis detection was used in assessing cell death of the tumour cells. Percent lysis of P815 cells was calculated as previously described [22].

Gene Expression in NK and CD8⁺T cells

Isolation of NK and CD8⁺T cells was done via MACS separation (Miltenyi Biotec GmbH; Bergisch-Gladbach, Germany) as specified by the manufacturer. Purity was determined on the flow cytometer using the Cell Quest software. Isolated NK cells were coated with PE-CD56CD16 and FITC-CD3 (BD Pharmingen, San Diego, CA) monoclonal antibodies to determine the purity of NK cells. To establish the purity of CD8⁺T cells, isolated CD8⁺T cells were stained and incubated with PE-CD8 and FITC-CD3 monoclonal antibodies (BD Pharmingen,

San Diego, CA). Cells were fast frozen in liquid nitrogen and kept in negative 80 degrees freezing conditions for further assessment. Total RNA extractions were performed using the RNeasy Mini Kit (Qiagen, Valencia, CA) and quantified on the NanoDrop 3300 (Thermo Scientific, Wilmington, DE). RNA was synthesised in to cDNA using the SuperScript[™] III First-Strand synthesis SuperMix for qRT-PCR (Invitrogen, Carlsbad, CA) as specified by the manufacturer and stored at negative 20°C for later analysis. RT-qPCR was performed using IQ SYBR Green Super Mix (Bio-Rad, Hercules, CA) with *GAPDH* as the housekeeping gene. Expression levels of granzyme A, granzyme K, perforin and interferon (IFN)- γ (*GZMA*, *GZMK*, *PRF1* and *IFN-G*) genes were collected and quantified using the iQCyler (Bio-Rad, Hercules, CA).

Quantification of NK Phenotypes

Distribution of NK cell phenotypes was assessed as previously described [23]. NK lymphocytes were isolated from whole blood via negative selection using Rosette-Sep Human Natural Killer Cell Enrichment Cocktail (StemCell Technologies, Vancouver, BC) and were labelled with CD56-FITC and CD16-PE monoclonal antibodies (BD Pharmingen, San Jose, CA).

VPACR2 Stimulation

Whole blood samples (10 mL) diluted with 1x PBS were layered over Ficoll-Hypaque for isolation of peripheral blood mononuclear cells. Cells were stimulated with or without 1 µg of Lipopolysaccharide (Invitrogen, Carlsbad, CA) and cultured for 48 hours. Cells were stained with vasoactive intestinal peptide receptor 2 (Sigma, St Louis, MO), FITC-IgG (Sigma, St Louis, MO) and CD4-PE anti-mouse monoclonal antibodies and analysed on the flow cytometer with settings for detecting monocytes and lymphocytes expressing the VPACR2 [24]. Percentage of cells expressing both CD4-PE and VIP2-FITC were recorded from these populations to determine the levels of VPACR2 expressed on these cells. In the lymphocyte gate specific reference was made for CD4⁺T cells.

Cytokine Determination

Isolated PBMCs were mitogenically stimulated with 1 µg of phytohemagglutinin and cultured at a concentration of 1×10^6 cells/mL for 72 hours. Following incubation, supernatants were removed and stored at -80°C for later assessment. T helper (Th)1, Th2 and Th17 cytokine expressions were investigated using the cytometric bead array kit (BD Pharmingen, San Diego, CA) [25] for determining levels of interleukin (IL)-2, IL-4, IL-6, IL-10, tumour necrosis factor (TNF)-α, INF-γ and IL-17A. The cytokines selected for this study although not conclusive, enough were selected to ascertain the Th1/Th2/Th17 mechanisms in CFS patients.

Regulatory T Cell Assessment

Expression of FoxP3 Tregs was determined on CD4⁺CD25⁺ cells. PBMC Cells were stained with monoclonal antibodies FITC-CD4 and APC-CD25 (BD Pharmingen, San Diego, CA) following which cells were

permeabilised and stained with anti-FoxP3 and PE-Foxp3 respectively and analysed via flow cytometry [26].

Statistical Analysis

Statistical analyses were performed using SPSS software version 16.0 (SPSS Inc, Chicago, USA). A sample size of 59 participants per group was required to obtain statistically significant results with an effect size of 0.5 and a power of 85%. All data represented in this study are reported as means plus or minus standard error of the mean (\pm SEM). Comparative assessments among participants (the CFS/ME and control subjects) were performed using the analysis of variance test (ANOVA) and independent sample t-test. All statistically significant results had *p*-values less than or equal to 0.05.

Ethical Clearance and Participant Selection

Approval for this study was granted after review by the Bond University Human Research Ethics Committee (RO852A).

Results

Of the 168 participants recruited 95 met the CDC criteria for CFS/ME and 50 qualified as healthy controls. Twenty-three participants were rejected because they did not meet the inclusion criteria for CFS/ME (Figure 1). 58.2% of CFS/ME patients indicated that they experienced 6 or more of the symptoms listed in the CDC criteria list and 21.4% experienced only 4 symptoms. The baseline characteristics of the participants are illustrated in Table 1.

Lymphocyte Cytotoxic Activity

NK and CD8⁺T (n = 71) cytotoxic activity measured as the ability of NK and CD8⁺T cells to effectively lyse

Table 1 Characteristics of participants in the study

| Parameters Measured | CFS/ME (n = 95) | Controls (n = 50) | <i>p</i> -values |
|---|----------------------------|----------------------------|------------------|
| Sex | Female 70.5% Male 29.5% | Female 57.7% Male 42.3% | |
| Mean Age | 46.47 \pm 11.7 | 41.9 \pm 9.6 | 0.11 |
| Height (cm) | 167.47 \pm 13.2 | 167.9 \pm 8.9 | 0.16 |
| Weight (lbs) | 169.8 \pm 140.7 | 159.8 \pm 46.5 | 0.11 |
| White Blood Cells | 5.8 \pm 1.4 | 6.3 \pm 1.8 | 0.68 |
| Lymphocyte (%) | 38 \pm 5.7 | 33.6 \pm 7.9 | 0.03 |
| Monocytes (%) | 5.90 \pm 1.4 | 5.6 \pm 2.2 | 0.30 |
| Granulocyte (%) | 56.3 \pm 7.1 | 60.8 \pm 8.2 | 0.06 |
| Lymphocyte ($\times 10^3/\mu\text{L}$) | 2.3 \pm 0.8 | 2.03 \pm 0.6 | 0.24 |
| Monocytes ($\times 10^3/\mu\text{L}$) | 0.8 \pm 4.2 | 0.34 \pm 0.2 | 0.51 |
| Granulocyte ($\times 10^3/\mu\text{L}$) | 3.3 \pm 1.0 | 3.87 \pm 1.5 | 0.21 |
| Red Blood Cells ($\times 10^6/\mu\text{L}$) | 4.3 \pm 0.5 | 4.56 \pm 0.4 | 0.08 |
| Haemoglobin (g/L) | 131.6 \pm 12.4 | 137.0 \pm 11.7 | 0.15 |
| Hematocrit (%) | 43.8 \pm 3.3 | 43.68 \pm 13.0 | 0.89 |

K562 and P815 cells respectively was significantly decreased ($p < 0.05$) among the CFS/ME patients compared to the control subjects (Figure 2). Similarly granzyme A expression was significantly decreased in both the NK and CD8⁺T cells in the CFS/ME population. However, IFN- γ and granzyme K were decreased only in the NK cells of the CFS/ME group compared to the healthy controls as shown in Figure 3A and 3B.

Altered NK Profiles in CFS/ME

For the purposes of this study NK phenotypes were classified into two, these are the CD56^{bright}CD16⁻ and CD56^{dim}CD16⁺NK cells. The number of NK cells expressing CD56^{bright}CD16⁻ was significantly lower ($p < 0.001$) in the CFS/ME patients compared to the control subjects (Figure 4C). However, CD56^{dim}CD16⁺NK cells remained unchanged across all groups (Figure 4C). The raw data are presented in 4A and 4B.

Profile of CD4⁺T cells Cytokines and VPACR2 in CFS/ME

After 72 hours of culture Th1 and Th2 cytokine secretions were considerably different between groups, however, Th17 cytokine IL-17A remained unchanged. However, IL-10, IFN- γ and TNF- α production was significantly elevated in the CFS/ME group compared to the control group (Figure 5). Other cytokines IL-2 and IL-6 although increased in the CFS/ME population were not statistically different between groups (Figure 5). IL-17A was similarly not significantly different between the two groups. FoxP3 secretion by Tregs was significantly higher in the CFS/ME group compared to healthy participants




Figure 2 Reduced lytic function of cytotoxic cells in CFS/ME. *In vivo* assessment of NK and CD8⁺T cell lysis (cytotoxic activity) of tumour cell lines K562 and P815 respectively in CFS/ME (black bars) in comparison to controls (white bars). Lytic activity is represented as percent (%) lysis on the y-axis. *Denotes statistical significant results. Data presented as mean \pm SEM.

(Figure 6). Incidentally, Treg cell counts were also higher in the CFS/ME group compared to the healthy population (0.77 ± 0.10 vs. 0.24 ± 0.02). Lymphocyte expression of VPACR2 was significantly higher in the CFS/ME patients compared to the control group (Figure 7).

Discussion

This is the first study to show significantly higher levels of VPACR2 receptors, CD4⁺CD25⁺Tregs and FoxP3⁺Treg expression in CFS/ME patients compared to healthy controls. In addition, CFS/ME patients had significantly higher levels of anti-inflammatory cytokine IL-10 and pro-inflammatory cytokines IFN- γ and TNF- α . This profile reflects significant and important immunological dysregulation that could explain some of the clinical symptoms, for example the ongoing sickness experience of CFS/ME patients.

This is the first study to provide a thorough investigation of the CD4⁺T cell profile in CFS/ME patients through the assessment of cytokine secretion and regulatory protein levels in particular VPACR2 receptors and FoxP3 expression. Cytokines are soluble proteins with either anti-inflammatory or pro-inflammatory effects. Equivocal cytokine expression patterns in CFS/ME patients have been reported without a definite identification as to which cytokines may be specifically linked to CFS/ME. Possible explanations for the inconsistencies in cytokine distribution across studies are the heterogeneous nature of the disorder and differences in analytical methods used. However, newer and more sensitive assays have been developed since the conflicting results were reported [17]. It has been suggested that the mechanism underlying CFS/ME may involve a shift in cytokine production leading to either a predominant Th1 or Th2 cytokine profile [27-29]. In the adaptive immune system, CD4⁺T cells subsets, Th1, Th2, Th17 and regulatory T cells (Tregs) are the main regulators of cytokine secretion and the inflammatory immune response. A bimodal Th1/Th2 response was observed in the present study. A predominant Th1 and Th17 immune response has been linked to the development or presence of an autoimmune disease whereas increases in Th2 cytokines suggest the presence of other systemic disorders [30,31]. Th1 cells secrete cytokines IFN- γ and IL-2 while Th2 cells secrete cytokines IL-4 and IL-10 [32] and Th17 secrete pro-inflammatory IL-17a, IL-17f and IL-22 [33,34]. Recent data on cytokine networks in CFS/ME show a predominant Th2/anti-inflammatory profile in CFS/ME with a weakened Th1 profile [17]. This study supports the presence of a possible imbalance in Th1/Th2 response in CFS/ME characterised by a significant increase in IL-10 together with significant increases in IFN- γ and TNF- α . Such increases in IL-10 are suggestive of a persistent chronic infectious state




Figure 3 mRNA Expression of cytotoxic molecules in NK and CD8⁺T cells. Quantitative reverse transcriptase (RT)-PCR demonstrated the relative expression of granzyme A, granzyme K, perforin and IFN- γ in NK (A) and CD8⁺T cells (B). In NK and CD8⁺T cells expression levels of *GZMA*, *GZMK* and *IFN-G* were decreased in CFS/ME (black bars) compared to the controls (white bars). *PRF1* was however increased in CFS group. *Denotes statistical significant results ($P \leq 0.05$). Data presented as mean \pm SEM.

and may be associated with a dampening of the NK and CD8⁺T cell immune response [22]. Others have shown that IL-10RA is differentially expressed in CFS/ME patients, highlighting a potential compromise in IL-10 function or its receptor in CFS/ME patients [35,36].

Nonetheless, increased levels of IL-10, IFN- γ and TNF- α indicate the presence of fungal, bacterial or viral infection [37]. Incidentally in HIV elevation in IL-10, IFN- γ and TNF- α denote the presence of a chronic infection and this correlated with viral load [38]. Similarly in CFS







Figure 4 Distribution of NK phenotypes. NK phenotypes that were examined are denoted as either NK Bright (CD56^{bright}CD16⁻) or NK Dim (CD56^{dim}CD16⁺). (A) The box plots represent the raw data of NK Bright cells in the two groups. CFS/ME patients were more decreased in the cell numbers for this particular NK phenotype. (B) However raw data of CD56^{dim}CD16⁺NK cells were examined in the control and CFS/ME groups, these were found to be similar. (C) Using the raw data from the flow cytometry results, total counts of NK cells were deduced. These measurements are plotted using bar graphs, CD56^{bright}CD16⁻NK cells are more reduced in the CFS/ME (black bars) group in comparison to the controls (white bars). *Denotes statistical significant results ($P \leq 0.05$). Data presented as mean \pm SEM.



such alterations in these cytokines may also suggest an increase in viral load and the occurrence of flu-like symptoms. An increase in IL-10 also may contribute to decreased cytotoxic activity observed in the NK and CD8⁺T cells [39,40]. The increase in pro-inflammatory cytokines such as TNF- α , may also depict the presence of an inflamed gut or irritable bowel syndrome in some CFS/ME patients [41]. Inflammation in the gut can alter the central nervous system [42,43] and affects various physiological mechanisms including neuropeptides.

The changes in both the Th1 and Th2 responses may suggest changes in the function of VN receptor VPACR2 which is a key promoter and stimulator of anti-inflammatory cytokines such as IL-10 [44]. It is important to note that VNs, VIP and PACAP have never been assessed in CFS/ME previously. These important neuropeptides increase IL-10 gene expression via the cAMP response element DNA binding complex pathway, therefore changes in VNs such as elevations in VPACR2 may suggest an increase in IL-10 [45]. Further, an increase in TNF- α and IFN- γ suggests an inability of the heightened VPACR2 to suppress TNF- α and IFN- γ secretion as these neuropeptides are noted to suppress pro-inflammatory cytokines while favouring anti-inflammatory

cytokine secretions [46]. Additionally, increases in VPACR2 potentially suggest changes in cAMP associated with the inflammatory immune response in CFS/ME. Although our study did not assess the levels of cAMP present in CFS/ME patients, VIP binding to its receptor, in this case VPACR2, is known to stimulate the presence of FoxP3⁺ which assists in regulating the T cell response. Thus it is consistent that heightened levels of VPACR2 will translate into heightened FoxP3 expression. FoxP3⁺ Tregs also secrete IL-10 which maintains the expression of FoxP3 in Tregs [47]. The increased expression of IL-10 and the relatively higher expression of FoxP3 together with significant increases in CD4⁺CD25⁺Tregs suppressive activity suggest a requirement to counter a significant pro-inflammatory response in these patients. While levels of viral antigens were not measured in this study, these observations may suggest a plausible prevalence in viral antigens, adjuvants or autoantibodies in the peripheral circulation of CFS/ME patients [48,49].

NK cytotoxic activity in CFS/ME has received much attention while only one study has examined CD8⁺T cell cytotoxic activity. Most studies found significant decreases in NK activity and one study found decreased CD8⁺T cell cytotoxic activity in a CFS/ME population compared with a control group. These findings are confirmed in our study. In a previous study [13] as well as this study in a larger population we have found that NK cytotoxic activity and CD56^{bright} NK phenotypes are decreased in CFS/ME patients. These atypical cytotoxic responses may be linked to compromised granule-mediated cell death pathways involving apoptotic mediators, perforin and granzymes. Perforin forms pore-like structures to facilitate the entry of granzymes into the target cell [50], and granzymes activate several apoptosis pathways that ensure effective killing of the target cell [51]. Perforin and granzymes have been shown to be decreased in both NK and CD8⁺T cells in CFS/ME [16,52]. In contrast both granzyme A and granzyme K were significantly reduced while perforin levels were elevated in both the NK and CD8⁺T cells of CFS/ME patients. Reduced cytotoxic activity may therefore be an important component of the immune dysregulation seen in CFS/ME.

Conclusions

These results illustrate a severely compromised immunomodulation mechanism in CFS/ME where attempts to regulate or restore immune homeostasis appear to be impaired. These findings suggest that certain immunological biomarkers as demonstrated in this study may be unique to CFS/ME. To date no routinely available clinical immunological markers have been identified that characterise CFS/ME, resulting in poor recognition and management of patients. The immunological abnormalities identified in our study can potentially fill this void

as potential biomarkers and assist clinicians and patients in diagnosis and management of this severely debilitating condition. These biomarkers may include NK phenotypes, NK activity, CD8⁺T cell activity, IL-10, IFN- γ TNF α , FoxP3 and VPACR2. These markers that seem to be unique to CFS/ME patients could assist in identifying them as a distinct population, enabling more appropriate clinical management and better targeted scientific investigations into the underlying pathomechanisms of the disease.

Acknowledgements

We thank the following individuals Prof. Chris Del Mar and Dr. Paul Glasziou for their invaluable contribution and feedback on the work presented here. We would also like to thank The Mason Foundation, Hunter Foundation and Queensland Government for funding this research.

Author details

¹Population Health and Neuroimmunology Unit, Faculty of Health Science and Medicine, Bond University, Robina, Queensland, Australia. ²Faculty of Health Science and Medicine, Bond University, Robina, Queensland, Australia. ³Queensland Health, Gold Coast Public Health Unit, Southport, Gold Coast, Queensland, Australia. ⁴Miami Veterans Affairs Medical Center, Miami, FL, USA.

Authors' contributions

Conceived and designed the experiments: EWB DRS SMMG. Performed the experiments: EWB SBR JK. Analysed the data: EWB. Supplied reagents/analysis tools: SMMG MVD KJA. Wrote the paper: EWB DRS SMMG MVD. Critically reviewed paper: SMMG, KJA, MVD, DRS, NGK. All authors read and approved the complete manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 1 April 2011 Accepted: 28 May 2011 Published: 28 May 2011

References

- Grinde B: Is chronic fatigue syndrome caused by a rare brain infection of a common, normally benign virus? *Med Hypotheses* 2008, **71**(2):270-274.
- Devanur LD, Kerr JR: Chronic fatigue syndrome. *J Clin Virol* 2006, **37**(3):139-150.
- Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S: The Economic impact of ME/CFS: Individual and societal costs. *Dyn Med* 2008, **7**:6.
- Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann Intern Med* 1994, **121**(12):953-959.
- Arnett SV, Alleva LM, Korossy-Horwood R, Clark IA: Chronic fatigue syndrome - A neuroimmunological model. *Med Hypotheses* 2011.
- Biswal B, Kunwar P, Natelson BH: Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling. *J Neurol Sci* 2011, **301**(1-2):9-11.
- Lakhan SE, Kirchgessner A: Gut inflammation in chronic fatigue syndrome. *Nutr Metab (Lond)* 2010, **7**:79.
- Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G: Immunological aspects of chronic fatigue syndrome. *Autoimmun Rev* 2009, **8**(4):287-291.
- Natelson BH, Weaver SA, Tseng CL, Ottenweller JE: Spinal fluid abnormalities in patients with chronic fatigue syndrome. *Clin Diagn Lab Immunol* 2005, **12**(1):52-55.
- Schutzer SE, Angel TE, Liu T, Schepmoes AA, Claus TR, Adkins JN, Camp DG, Holland BK, Bergquist J, Coyle PK, Smith RD, Fallon BA, Natelson BH: Distinct cerebrospinal fluid proteomes differentiate post-treatment Lyme disease from chronic fatigue syndrome. *PLoS One* 2011, **6**(2):e17287.

11. Sorensen B, Jones JF, Vernon SD, Rajeevan MS: **Transcriptional control of complement activation in an exercise model of chronic fatigue syndrome.** *Mol Med* 2009, **15**(1-2):34-42.
12. Nijs J, van Eupen I, Vandecauter J, Augustinus E, Bleyen G, Moorkens G, Meeus M: **Can pacing self-management alter physical behavior and symptom severity in chronic fatigue syndrome? A case series.** *J Rehabil Res Dev* 2009, **46**(7):985-996.
13. Brenu EW, Staines DR, Baskurt OK, Ashton KJ, Ramos SB, Christy RM, Marshall-Gradisnik SM: **Immune and hemorheological changes in chronic fatigue syndrome.** *J Transl Med* 2010, **8**:1.
14. Fletcher MA, Zeng XR, Maher K, Levis S, Hurwytz B, Antoni M, Broderick G, Klimas NG: **Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26.** *PLoS One* 2010, **5**(5):e10817.
15. Klimas NG, Salvato FR, Morgan R, Fletcher MA: **Immunologic abnormalities in chronic fatigue syndrome.** *J Clin Microbiol* 1990, **28**(6):1403-1410.
16. Maher KJ, Klimas NG, Fletcher MA: **Chronic fatigue syndrome is associated with diminished intracellular perforin.** *Clin Exp Immunol* 2005, **142**(3):505-511.
17. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA: **A formal analysis of cytokine networks in Chronic Fatigue Syndrome.** *Brain Behav Immun* 2010.
18. Kuratsune H: **Overview of chronic fatigue syndrome focusing on prevalence and diagnostic criteria.** *Nippon Rinsho* 2007, **65**(6):983-990.
19. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C: **VIP-PACAP system in immunity: new insights for multitarget therapy.** *Ann N Y Acad Sci* 2006, **1070**:51-74.
20. Staines DR: **Is chronic fatigue syndrome an autoimmune disorder of endogenous neuropeptides, exogenous infection and molecular mimicry?** *Med Hypotheses* 2004, **62**(5):646-652.
21. Aubry JP, Blaecke A, Lecoanet-Henchoz S, Jeannin P, Herbault N, Caron G, Moine V, Bonnefoy JY: **Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity.** *Cytometry* 1999, **37**(3):197-204.
22. White L, Krishnan S, Strbo N, Liu H, Kolber MA, Lichtenheld MG, Pahwa RN, Pahwa S: **Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV).** *Blood* 2007, **109**(9):3873-3880.
23. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaehri BA, Ghayur T, Carson WE, Caligiuri MA: **Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.** *Blood* 2001, **97**(10):3146-3151.
24. Sun W, Hong J, Zang YC, Liu X, Zhang JZ: **Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.** *Int Immunol* 2006, **18**(12):1691-1700.
25. Collins DP, Luebering BJ, Shaut DM: **T-lymphocyte functionality assessed by analysis of cytokine receptor expression, intracellular cytokine expression, and femtomolar detection of cytokine secretion by quantitative flow cytometry.** *Cytometry* 1998, **33**(2):249-255.
26. Okwor I, Muleme H, Jia P, Uzonna JE: **Altered proinflammatory cytokine production and enhanced resistance to Trypanosoma congolense infection in lymphotoxin beta-deficient mice.** *J Infect Dis* 2009, **200**(3):361-369.
27. Skowera A, Cleare A, Blair D, Bevis L, Wessely SC, Peakman M: **High levels of type 2 cytokine-producing cells in chronic fatigue syndrome.** *Clin Exp Immunol* 2004, **135**(2):294-302.
28. Swanink CM, Vercoulen JH, Galama JM, Roos MT, Meyaard L, van der Ven-Jongekrijg J, de Nijs R, Bleijenberg G, Fennis JF, Miedema F, van der Meer JW: **Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome.** *J Infect Dis* 1996, **173**(2):460-463.
29. Nakamura T, Schwander SK, Donnelly R, Ortega F, Togo F, Broderick G, Yamamoto Y, Cherniack NS, Rapoport D, Natelson BH: **Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia.** *Clin Vaccine Immunol* 2007, **15**(4):582-587.
30. Drlulovic J, Savic E, Pekmezovic T, Mesaros S, Stojisavljevic N, Dujmovic-Basuroski I, Kostic J, Vasic V, Stojkovic MM, Popadic D: **Expression of T(H)1 and T(H)17 cytokines and transcription factors in multiple sclerosis patients: Does baseline T-Bet mRNA predict the response to interferon-beta treatment?** *J Neuroimmunol* 2009, **215**(1-2):90-95.
31. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN: **Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma.** *Clin Cancer Res* 2009, **15**(6):1931-1939.
32. Zhu J, Paul WE: **CD4 T cells: fates, functions, and faults.** *Blood* 2008, **112**(5):1557-1569.
33. Paust HJ, Turner JE, Steinmetz OM, Peters A, Heymann F, Holscher C, Wolf G, Kurts C, Mittrucker HW, Stahl RA, Kurts C, Panzer U: **The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis.** *J Am Soc Nephrol* 2009, **20**(5):969-979.
34. Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, Moles JP, Danger Y, Ravon E, Lesaux S, Yssel H, Gascan H: **Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes.** *J Immunol* 2008, **180**(11):7423-7430.
35. Kaushik N, Fear D, Richards SC, McDermott CR, Nuwaysir EF, Kellam P, Harrison TJ, Wilkinson RJ, Tyrrell DA, Holgate ST, Kerr JR: **Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome.** *J Clin Pathol* 2005, **58**(8):826-832.
36. Kerr JR: **Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis.** *Curr Rheumatol Rep* 2008, **10**(6):482-491.
37. Couper KN, Blount DG, Riley EM: **IL-10: the master regulator of immunity to infection.** *J Immunol* 2008, **180**(9):5771-5777.
38. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP: **Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection.** *AIDS Res Hum Retroviruses* 2006, **22**(8):757-762.
39. den Haan JM, Kraal G, Bevan MJ: **Cutting edge: Lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response.** *J Immunol* 2007, **178**(9):5429-5433.
40. Szkaradkiewicz A, Karpinski TM, Drewns M, Borejsza-Wysocki M, Majewski P, Andrzejewska E: **Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer.** *J Biomed Biotechnol* 2010, 901564.
41. Scully P, McKernan DP, Keohane J, Groeger D, Shanahan F, Dinan TG, Quigley EM: **Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity.** *Am J Gastroenterol* 2010, **105**(10):2235-2243.
42. Goehler LE, Lyte M, Gaykema RP: **Infection-induced viscerosensory signals from the gut enhance anxiety: implications for psychoneuroimmunology.** *Brain Behav Immun* 2007, **21**(6):721-726.
43. Lakhani SE, Kirchgessner A: **Gut inflammation in chronic fatigue syndrome.** *Nutr Metab (Lond)* 7:79.
44. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D: **Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.** *J Immunol* 1999, **162**(3):1707-1716.
45. Pozo D, Delgado M, Martinez M, Guerrero JM, Leceta J, Gomariz RP, Calvo JR: **Immunobiology of vasoactive intestinal peptide (VIP).** *Immunol Today* 2000, **21**(1):7-11.
46. Pozo D, Delgado M: **The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?** *FASEB J* 2004, **18**(12):1325-1334.
47. Gonzalez-Rey E, Delgado M: **Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis.** *Trends Mol Med* 2007, **13**(6):241-251.
48. Nancy AL, Shoenfeld Y: **Chronic fatigue syndrome with autoantibodies—the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant.** *Autoimmun Rev* 2008, **8**(1):52-55.
49. Buskila D, Atzeni F, Sarzi-Puttini P: **Etiology of fibromyalgia: the possible role of infection and vaccination.** *Autoimmun Rev* 2008, **8**(1):41-43.
50. Scott GB, Meade JL, Cook GP: **Profiling killers; unravelling the pathways of human natural killer cell function.** *Brief Funct Genomic Proteomic* 2008, **7**(1):8-16.
51. Chowdhury D, Lieberman J: **Death by a thousand cuts: granzyme pathways of programmed cell death.** *Annu Rev Immunol* 2008, **26**:389-420.
52. Saiki T, Kawai T, Morita K, Ohta M, Saito T, Rokutan K, Ban N: **Identification of marker genes for differential diagnosis of chronic fatigue syndrome.** *Mol Med* 2008, **14**(9-10):599-607.

doi:10.1186/1479-5876-9-81

Cite this article as: Brenu et al.: Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. *Journal of Translational Medicine* 2011 9:81.